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Forkhead L2 (Foxl2) is expressed in ovarian granulosa cells and participates in steroidogenesis by
transcriptionally regulating target genes such as steroidogenic acute regulatory protein (StAR)
and CYP19A1. In this study, a direct link between microRNA-133b (miR-133b) and Foxl2-mediated
estradiol release in granulosa cells was established. miR-133b was involved in follicle-stimulating
hormone (FSH)-induced estrogen production. Luciferase assays conﬁrmed that miR-133b was
bound to the 30 untranslated region (30UTR) of Foxl2 mRNA. Consistent with this ﬁnding, miR-
133b overexpression reduced the Foxl2 levels. Furthermore, miR-133b inhibited Foxl2 binding to
the StAR and CYP19A1 promoter sequences. These results demonstrate that miR-133b down-regu-
lates Foxl2 expression in granulosa cells by directly targeting the 30UTR, thus inhibiting the Foxl2-
mediated transcriptional repression of StAR and CYP19A1 to promote estradiol production.
Crown Copyright  2013 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. All rights reserved.1. Introduction
Female fertility depends on the relationships and balance
among many complicated physiological mechanisms [1]. Among
these processes, premature ovarian failure (POF), which causes
amenorrhea, hypoestrogenism and elevated gonadotropins before
40 years of age, is a major cause of infertility [2].
The etiology of ovarian failure is sophisticated. The forkhead
box L2 (Foxl2) gene is reportedly mutated in patients with bleph-
arophimosis–ptosis–epicanthus inversus syndrome (BPES), which
is associated with POF in females [3]. In Foxl2-null mice, primor-
dial follicle arrest occurs as ovarian granulosa cell differentiationis blocked at the squamous to cuboidal transition, resulting in
ovarian failure and infertility [4]. As the earliest known marker
of ovarian differentiation, Foxl2 plays a signiﬁcant role in early
ovarian development and female sex determination as well as in
postnatal ovarian somatic cell differentiation and follicle mainte-
nance [5]. Foxl2 is expressed in the ovaries and is required for
granulosa cell function [6] partly through regulation of steroido-
genesis genes, including StAR, CYP19A1, CYP11A1, and CYP17
[5,7]. The steroidogenic acute regulatory (StAR) protein facilitates
cholesterol transport to supply substrates for steroid hormone bio-
synthesis [8], while CYP19A1 is a rate-limiting enzyme in estrogen
production, suggesting that Foxl2 may have a regulatory role in
estrogen secretion.
Recent studies indicated that altered microRNA (miRNA)
expression levels correlate with diverse pathological conditions.
miRNAs are a family of small, non-coding RNAs [9], and they cause
mRNA degeneration or gene silencing by binding to the comple-
mentary seed sequence in the 30 untranslated regions (30UTRs) of
the target genes, resulting in post-transcriptional repression of
gene expression [10]. Lei et al. determined that conditional Dicer1
inactivation in the follicular granulosa cells impaired follicular
development [11]. Dicer is a ribonuclease III that is essential for
mature functional miRNA synthesis, and it is conceivable that miR-
NAs play a critical role in steroidogenesis, apoptosis, and ovulation
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145 and miR-181a suppressed mouse granulosa cell proliferation
by targeting the 30UTRs of activin receptor type IB (ACVRIB) and
activin receptor type IIA (ACVRIIA), respectively [13,14]. Yin et al.
determined that miR-383 enhanced estradiol release from
granulosa cells by targeting RNA binding motif, single stranded
interacting protein 1 (RBMS1) [15]. miR-378 and miR-224 report-
edly regulated estradiol production by targeting the aromatase
transcript [16,17]. miR-133b is reportedly instrumental for cell
proliferation, invasion, differentiation, and apoptosis [18,19]. How-
ever, the role of miR-133b in the ovary remains uncharacterized.
Based on the online miRNA target gene prediction program
TargetScan (http://www.targetscan.org/), the 30UTRs of human
and mouse Foxl2 mRNA were aligned with the sequence of mature
miR-133b, suggesting that Foxl2 was a putative target gene of miR-
133b. Thus, we identiﬁed a novel regulatory role for miR-133b on
Foxl2 and provided a possible mechanism for miR-133b-mediated
estrogen release in granulosa cells.Table 1
Oligonucleotide primer sequences for quantitative real-time PCR.
Genes Primers (50–30) Products size (bp)
miR-133b ACACTCCAGCTGGGTTTGGTCCCCTTCAAC 65
GGTGTCGTGGAGTCGGCAATTCAGTTGAG
U6 CTCGCTTCGGCAGCACA 64
AACGCTTCACGAATTTGCGT
hFoxl2 TACTCGTACGTGGCGCTCAT 162
CTCGTTGAGGCTGAGGTTGT
hStAR TGAGGCAATCGCTCTATCCT 184
AAGGGTGGTTCTTCGTCCTT
hCYP19A1 CAGAGGCCAAGAGTTTGAGG 242
ACACTAGCAGGTGGGTTTGG
h18S rRNA CGGCTACCACATCCAAGGAA 186
CTGGAATTACCGCGGCT
mFoxl2 GAGCGGTCCCCCACCCCTATC 169
CGGAGGCGACAAAGCGGAGT
mStAR ACCCTTGAGCACCTCAGCACT 171
CCCATCCACCCGGGACTGGAA
mCYP19A1 TGTGTTGACCCTCATGAGACA 190
CTTGACGGATCGTTCATACTTTC
m18S rRNA ATGGCCGTTCTTAGTTGGTG 183
CGGACATCTAAGGGCATCAC2. Materials and methods
2.1. Animals
ICR mice were purchased and maintained as previously
described [13]. All of the animal experiments were performed in
accordance with the guidelines that were provided and the proto-
cols that were approved by the Experimental Animals Manage-
ment Committee (Jiangsu Province, China).
2.2. Mouse primary granulosa cell (mGC) collection and culture
Mouse granulosa cells were collected from the ovaries of 21-
day-old mice and cultured as previously mentioned [13,20].
2.3. Cell lines
The KGN, HEK293T, and HEK293A cell lines were maintained as
described previously [13,21].
2.4. Recombinant adenovirus construction
An adenovirus encoding a DNA fragment encompassing the has-
miR-133b gene (Ad-miR-133b) was generated using the AdMax
(Microbix Biosystems, Inc., Toronto, Canada) system. An adenovi-
rus encoding LacZ (Ad-LacZ) was purchased from Clontech (Palo
Alto, CA, USA). The viruses were packaged, ampliﬁed, puriﬁed,
and titered as described previously [13].
2.5. miR-133b inhibitor treatment
Granulosa cells were transfected with miR-133b inhibitors
(Ribobio Biotech Corporation, Guangzhou, China) at 60% conﬂu-
ence using the Lipofectamine 2000 reagent (Invitrogen, Carlsbad,
CA, USA). Cells and spent media were collected after 48 h.
2.6. Analysis of estradiol levels
Granulosa cells were seeded into 12-well plates and either in-
fected with virus or transfected with plasmid DNA. After 6 h, the
medium was replaced with phenol red-free DMEM/F12 (Gibco
BRL/Invitrogen, Carlsbad, CA, USA) supplemented with 10% char-
coal/dextran-treated FBS (Gibco) and androstanolone (Sigma, St.
Louis, MO, USA) at 2 lM. The spent media were collected at the
indicated time points, and the estradiol levels were assayed using
the Access Immunoassay System (Beckman Coulter, Inc., Brea, CA).2.7. RNA isolation and quantitative real-time PCR
Total RNA was extracted using the TRIzol reagent (Invitrogen).
cDNA was synthesized from 1 lg of puriﬁed RNA using the Prime-
Script RT reagent kit (Bio-Rad Laboratories, Hercules, CA, USA). The
quantitative polymerase chain reaction (PCR) primers are listed in
Table 1. Each reaction contained 1 ll of RT product, 10 ll of SYBR
Green PCR Master Mix (Bio-Rad), and 500 nM of the forward and
reverse primers. Real-time PCR was performed for 40 cycles
(genes: 95 C for 10 s, 60 C for 30 s, and 72 C for 30 s after an ini-
tial 3 min incubation at 95 C; miRNAs: 95 C for 15 s and 60 C for
1 min after an initial 15 min incubation at 95 C). The data were
analyzed according to the 2DDCT method [22], and the fold change
in the expression of each gene was normalized to the endogenous
control (U6 or 18S rRNA).
2.8. Western blot
Proteins were harvested and separated on SDS–PAGE gels as
previously described [23]. Immunoblotting was performed with
antibodies against Foxl2 (1:500; Abcam, Cambridge, MA, USA),
hStAR (1:5000; Epitomics, Burlingame, CA, USA), mStAR (1:5000;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), goat anti-rab-
bit (1:5000; Genescript, Piscataway, NJ, USA), rabbit anti-goat
(1:1000; Bio-Rad), Myc-HRP antibody (1:5000, Abcam), and b-actin
(1:5000; Bioworld Technology Inc., Minneapolis, MN, USA). An en-
hanced chemiluminescence detection kit (Millipore, Billerica, MA,
USA) was used for Immunodetection.
2.9. Plasmid construction
Based on the human Foxl2 mRNA sequence (accession No.
NM_023067.3), approximately 971 bp of the Foxl2 30UTR (from
+1850 to +2820) containing the putative miR-133b binding sites
(from +2047 to +2053 and from +2810 to +2816) was PCR ampli-
ﬁed from human ovary cDNA with the following primers:
50-ATCGTCTAGAAGCGTCTCCTGCCCAAATTC-30 and 50-CGCGTCTA-
GAAAATTTGGTCCCCCAAACAAC-30. The product was cloned into
the pGL3-promoter luciferase reporter plasmid (Promega, Madi-
son, WI, USA) and sequenced to conﬁrm the resulting plasmid
pGL3-Promoter-Foxl2-30UTR.
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putative miR-133b binding sites located in the 30UTR of the Foxl2
sequence (mutant 1 +2810 to +2816, GGACCAA to GCAGCAA;
mutation 2 +2047 to +2053 and +2810 to +2816, GGACCAA to
GCAGCAA). The mutant 1 sequence was ampliﬁed from the
pGL3-Promoter-Foxl2-30UTR plasmid with the following primers:
50-ATCGTCTAGAAGCGTCTCCTGCCCAAATTC-30 and 50-CGCGTCTA-
GAAAATTTGCTGCCCCAAACAACAAGCTA-30. The mutant sequence
was cloned into the luciferase reporter plasmid as pGL3-Pro-
moter-Foxl2-30UTRmutant 1. The plasmid mutant 2 was generated
frommutant 1 using the QuikChangeMulti Site-Directed Mutagen-
esis Kit (Stratagene, La Jolla, CA, USA).
The full-length coding sequence of human Foxl2 was ampliﬁed
from human ovary cDNA with the primers 50-TATAGAATTCCA
TGATGGCCAGCTACCCCGA-30 and 50-TATACTCGAGTCAGAGATCGA
GGCGCGAAT-30. The PCR product was cloned into a pCS2-6Myc
vector that had been digested with EcoRI/XhoI, and the resulting
plasmid was pCS2-6Myc-Foxl2.
The DNA fragment containing both the human Foxl2 full-length
coding sequence and the 30UTR with the putative miR-133b
binding sites was constructed using the overlap PCR method. The
product was also cloned using the same method described above
and was sequenced as pCS2-6Myc-Foxl2-30UTR.
2.10. Transient transfection and luciferase reporter assays
Preconﬂuent (70%) HEK293T cells or mGCs in 12-well plates
were transfected with the indicated plasmids using Nanofectin
(PAA, Pasching, Austria) or Lipofectamine 2000. The luciferase
activity measurement was performed as previously described [24].
2.11. Chromatin immunoprecipitation (ChIP) assays
Quantitative ChIP was performed following a protocol described
previously [24]. Brieﬂy, KGN cells were infected with Ad-LacZ or
Ad-miR-133b (100 MOI) for 48 h. The cells were then crosslinked
with 1% formaldehyde and stopped with 0.125 M glycine. After col-
lection in lysis buffer A, the cells were pelleted by centrifugation.
The pellets were lysed in nuclear lysis buffer B and sonicated in
ice to yield genomic DNA fragments of approximately 200 bp.
Pre-cleared supernatants were then incubated with Foxl2 or con-
trol antibodies and rotated at 4 C overnight. Immune complexes
were pulled down with protein A/G beads (Upstate Biotechnology,
Lake Placid, NY, USA) and eluted by incubation in elution buffer.
Crosslink reversal was performed by incubation with 0.3 M NaCl.
After protein digestion, the DNA was puriﬁed and used as a tem-
plate for quantitative real-time PCR. The primers sets included
50-TGAGGCAATCGCTCTATCCT-30 and 50-AAGGGTGGTTCTTCGTC
CTT-30 (spanning 119/+64 bp of human StAR promoter, overlap-
ping the putative Foxl2 binding site), 50-CAGCAGATCAGAGGGAG-
GAG-30 and 50-CATTGTTTCCAGCCCTCAGT-30 (spanning 2937/
2783 bp of human StAR promoter, negative control region),
50-TACAGCACCCTCTGAAGCAA-30 and 50-GCACGATGCTGGTGATGT-
TA-30 (spanning 83/+89 bp of the human CYP19A1 promoter,
overlapping the putative Foxl2 binding site), and 50-TGGCATGA-
TAAAGAGCATGG-30 and 50-CATCTTCACGACAAGCCTGA-30 (span-
ning 2997/2825 bp of the human CYP19A1 promoter, negative
control region).
2.12. Statistical analysis
The data are expressed as the mean ± S.E.M. from at least three
independent experiments. Student’s t-test was used for compari-
son between the mean values of two groups, and ANOVA was per-
formed to detect differences among more than two groups. A P
value <0.05 was considered to be statistically signiﬁcant.3. Results
3.1. miR-133b stimulates estrogen production in granulosa cells
To identify whether miR-133b is relevant of follicle-stimulating
hormone (FSH)-induced steroidogenesis in the ovary, we treated
KGN cells with FSH and assayed spent media and cells at the
indicated time points. Compared with the control group, FSH stim-
ulated estradiol release in KGN cells 24, 36, and 48 h after treat-
ment. miR-133b expression was also increased (Fig. 1A).
We next examined estradiol concentration in culture media
from KGN or mGCs that had been infected with Ad-miR-133b.
The results demonstrated that in human and mouse granulosa
cells, miR-133b overexpression (Fig. 1B) upregulated estradiol lev-
els in a concentration-dependent manner (Fig. 1C).
To provide further evidence for the functional signiﬁcance of
miR-133b in the regulation of estradiol release in granulosa cells,
we performed loss-of-function studies using miR-133b inhibitor
treatment. As demonstrated in Fig. 1D, when endogenous miR-
133b expression was decreased to 35% in KGN and 32% in mGCs,
the estradiol concentration was also reduced in two types of gran-
ulosa cells (Fig. 1E). In addition, FSH was used to induce miR-133b
expression followed by miR-133b inhibitor treatment in KGN cells
(Fig. 1F). Analysis of estradiol levels in cell media was performed to
demonstrated that FSH-induced estradiol increase was impaired
by miR-133b inhibition. Taken together, these data indicate the
functional role of miR-133b in FSH-induced estrogen secretion.
3.2. miR-133b upregulates StAR and CYP19A1 expression in granulosa
cells
StAR and CYP19A1 are critical genes that are involved in estro-
gen biosynthesis [8]. To address the mechanism of steroidogenesis
stimulation by miR-133b, we performed real-time PCR analysis to
demonstrate that miR-133b overexpression increased StAR and
CYP19A1 mRNA levels in human and mouse granulosa cells
(Fig. 2A and C). Western blots demonstrated that StAR protein
expression was also upregulated in a dose-dependent manner
(Fig. 2B and D). In contrast, StAR and CYP19A1 expression was
attenuated in a concentration-dependent manner with decreasing
expression level of endogenous miR-133b (Fig. 2E–H). These ﬁnd-
ings suggest that miR-133b promotes estrogen biosynthesis by
increasing the expression of the steroidogenesis-associated genes
StAR and CYP19A1.
3.3. miR-133b regulates estrogen synthesis via inhibiting Foxl2
expression
To investigate the mechanism of StAR and CYP19A1 regulation
by miR-133b, we used the prediction software program Target-
Scan and found that neither StAR nor CYP19A1 was a candidate
target gene of miR-133b. However, Foxl2, a transcriptional repres-
sor of StAR and CYP19A1 [25,26], might be directly targeted by
miR-133b. As shown in Fig. 3A, there are two putative target sites
(seed sequences) in the 30UTR of human Foxl2 mRNA, which
aligned with the sequence of mature miR-133b. The site that
was located from +2810 to +2816 was highly conserved between
humans and mice. Thus, we constructed a luciferase reporter
plasmid with the human Foxl2 30UTR that contained these two
seed sequences (Fig. 3B). After co-transfection with pSilencer-
CMV-miR-133b into HEK293T cells, luciferase activity was
signiﬁcantly decreased by miR-133b overexpression in a concen-
tration-dependent manner (Fig. 3C). Furthermore, miR-133b
inhibitor treatment had an stimulatory effect on luciferase activ-
ity in mGCs (Fig. 3D). To identify the speciﬁc sites of miR-133b
action within the Foxl2 30UTR, the two putative miR-133b target
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Consistent with our earlier ﬁnding, miR-133b suppressed the
luciferase activity from the wild-type plasmid. However, this
inhibition was abolished when the cells were transfected with
plasmid mutants 1 or 2 (Fig. 3E). These data suggest that theFig. 1. miR-133b stimulated estrogen production in granulosa cells. (A) The KGN cells we
media were collected for the estradiol level measurements, and the cells were collect
compared with the control group. (B and C) The KGN cells and mGCs were infected with
measure miR-133b expression, and the culture media were used for the estradiol level m
KGN cells and mGCs were transfected with miR-133b inhibitors at concentrations of 0, 5
⁄P < 0.05, ⁄⁄P < 0.01 compared with the control group. (F) The KGN cells were treat
concentrations of 0, 50, and 100 nM. miR-133b expression and estradiol levels were meconserved site that is located from +2810 to +2816 plays a max-
imal role in miR-133b targeting.
Accordingly, we wondered whether altered miR-133b levels
could regulate Foxl2 expression. As shown in Fig. 4A and B, Foxl2
mRNA and protein expression was upregulated by miR-133bre treated with 20 ng/ml FSH for 0, 24, 36, and 48 h. At each time point, the culture
ed for miR-133b expression measurements by real-time PCR. ⁄P < 0.05, ⁄⁄P < 0.01
Ad-miR-133b at an MOI of 0, 25, 50, and 100. After 48 h, the cells were collected to
easurements. ⁄P < 0.05, ⁄⁄P < 0.01 compared with the Ad-LacZ group. (D and E) The
0, and 100 nM. miR-133b expression and estradiol levels were measured after 48 h.
ed with or without 20 ng/ml FSH and transfected with miR-133b inhibitors at
asured 48 h later. ⁄P < 0.05, ⁄⁄P < 0.01.
Fig. 2. miR-133b increased StAR and CYP19A1 expressions in granulosa cells. (A and C) The KGN cells and mGCs were infected with Ad-miR-133b at an MOI of 0, 25, 50, and
100. After 48 h, the cells were collected to measure the StAR and CYP19A1 mRNA expression levels by real-time PCR. ⁄P < 0.05, ⁄⁄P < 0.01 compared with the Ad-LacZ group. (B
and D) Western blots were performed to measure the StAR protein levels. (E and G) miR-133b inhibitors were transfected into the KGN cells and mGCs at concentrations of 0,
50, and 100 nM. Forty-eight hours after treatment, real-time PCR was performed to measure the StAR and CYP19A1 mRNA expression levels. ⁄P < 0.05, ⁄⁄P < 0.01 compared
with the control group. (F and H) The StAR protein levels were examined by western blot. Relative protein levels were measured by densitometry using Quantity One
Software and normalized to b-actin, the control group; the ratios were presented above the Western blot bands.
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miR-133b inhibitor substantially reduced the Foxl2 levels in a
concentration-dependent manner (Fig. 4C and D). miR-133b signif-
icantly suppressed the expression of the Myc-tagged Foxl2 con-
taining the 30UTR to 47%, while the protein expression of Foxl2
without the 30UTR was not affected, indicating that the Foxl2 30UTR
was responsive to the inhibitory effect of miR-133b (Fig. 4E).
Moreover, the estradiol levels in the mGCs were decreased by
Foxl2 overexpression and increased by miR-133b overexpression
(Fig. 4E). However, when Foxl2 and miR-133b were overexpressedsimultaneously, the Foxl2-mediated estrogen production inhibi-
tion was partly reversed by miR-133b.
3.4. miR-133b suppresses the Foxl2-mediated transcriptional
inhibition of StAR and CYP19A1
We next performed quantitative ChIP experiments to investi-
gate whether miR-133b affected Foxl2 binding to the StAR and
CYP19 promoters. Consistent with previous ﬁndings about
transcriptional repression by Foxl2 [5,25,26], Foxl2 overexpression
Fig. 3. Identiﬁcation of the putative miR-133b binding sites within the Foxl2 30UTR. (A) Putative binding sites for miR-133b in the 30UTR of human and mouse Foxl2 mRNA.
Potential complementary residues were demonstrated by uppercase letters. The seed sequences were demonstrated by underlining. The transcriptional start site was denoted
as +1. The miR-133b mature sequences were identical for the two species. (B) The mutant seed sequences in the human Foxl2 mRNA 30UTR were shown in lowercase letters.
(C) The HEK293T cells were transfected with pSilencer-CMV-miR-133b and Foxl2 30UTR-luciferase constructs. (D) The mGCs were transfected with 100 nM miR-133b
inhibitors and 300 ng Foxl2 30UTR-luciferase constructs. (E) HEK293T cells were transfected with pSilencer-CMV-miR-133b and the wild type/mutant 1/mutant 2 Foxl2
30UTR-luciferase constructs. Forty-eight hours after transfection, luciferase assays were performed and normalized by constitutive Renilla luciferase expression. ⁄P < 0.05,
⁄⁄P < 0.01; NS, no signiﬁcant difference.
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KGN cells. Fig. 5C and D showed that chromatin fragments with
potential Foxl2-binding sites, but not the negative control region,
speciﬁcally co-precipitated with Foxl2 from cell lysates. In addi-
tion, this precipitation was attenuated by miR-133b, indicating
that the Foxl2-mediated transcriptional suppression of StAR and
CYP19A1 was impaired. Taken together, these data suggest that
miR-133b promotes estrogen synthesis in granulosa cells bytargeting Foxl2-mediated transcriptional regulation of StAR and
CYP19A1.
4. Discussion
The effects of miRNAs on ovarian function primarily occur
through their actions on somatic cells, such as granulosa cells
[12]. During follicle development, FSH enhances estrogen and
Fig. 4. The effects of miR-133b overexpression and inhibition on Foxl2 expressions in granulosa cells. (A and B) The KGN cells and mGCs were infected with Ad-miR-133b at
an MOI of 0, 25, 50 and 100 for 48 h. Foxl2 mRNA expression was measured by real-time PCR and protein levels were examined by Western blot. ⁄P < 0.05 compared with the
Ad-LacZ group. (C and D) The KGN cells and mGCs were transfected with miR-133b inhibitors at a concentration of 0, 50, and 100 nM. After 48 h, real-time PCR was performed
to measure Foxl2 mRNA expression and Western blots were performed to measure the Foxl2 protein levels. ⁄P < 0.05, ⁄⁄P < 0.01 compared with the control group. (E) The
mGCs were ﬁrst infected with Ad-miR-133b or Ad-LacZ and were then transfected with Myc-tagged plasmids harboring the Foxl2 mRNA sequence with or without the 30UTR.
After 48 h, the Foxl2 protein levels were measured by immunoblotting with HRP-conjugated anti-Myc antibodies. (F) The mGCs were ﬁrst infected with Ad-miR-133b or Ad-
LacZ and were then transfected with pCS2-Myc-Foxl2 or empty vector. After 48 h, the culture media were collected for estradiol level measurement. ⁄P < 0.05. Relative protein
levels were measured by densitometry using Quantity One Software and normalized to b-actin, the control group; the ratios were presented above the Western blot bands.
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cycle and reproduction. Yao et al. demonstrated that miR-29a
and miR-30d were signiﬁcantly downregulated during FSH-in-
duced progesterone secretion in rat granulosa cells, indicating that
they may have possible effects on progesterone synthesis [27]. In
this study, we demonstrated that miR-133b was involved in FSH-
induced estrogen secretion. Furthermore, Foxl2, a key modulator
of steroidogenesis, was negatively regulated by miR-133b. Differ-
ent granulosa cells, such as KGN cells and mGCs, were used in this
study to evaluate and conﬁrm the interactions between miR-133b
and Foxl2. This study provides the ﬁrst evidence of the regulatory
effects of miR-133b on estrogen synthesis in ovarian granulosa
cells.
FSH controls granulosa cell development during folliculogenesis
by stimulating their proliferation, differentiation, and follicular an-
trum formation [28]. FSH-mediated actions are accomplished bythe actions of the adenosine-30:50-monophosphate (cAMP)/protein
kinase A (PKA)/cAMP response element binding protein (CREB)
pathway in addition to other signaling cascades, including extra-
cellular regulated kinases (ERKs), mitogen-activated protein
kinases (MAPKs), phosphoinositide 3-kinase (PI3K), and calcium-
mediated signaling [29]. In our study, FSH promoted miR-133b
expression and estradiol levels in KGN cells, and FSH-induced
estradiol secretion was impaired by miR-133b inhibitor treatment,
demonstrating that FSH inﬂuences estrogen synthesis partly by its
effect on miR-133b expression. Additional detailed studies on miR-
133b involvement in FSH signaling pathways need to be performed
in the future.
The high conservation of Foxl2 sequences and mammalian
expression suggests a key role in ovarian development and
function [30,31]. Either human or mouse Foxl2 can function as a
transcriptional repressor of StAR and CYP19A1, likely by binding
Fig. 5. miR-133b suppressed the Foxl2-mediated transcriptional inhibition of StAR and CYP19A1. The KGN cells were transfected with 900 ng pCS2-Myc-Foxl2 plasmid or
empty vector. After 48 h, real-time PCR was performed to measure StAR (A) and CYP19A1 (B) mRNA expression. ⁄P < 0.05, ⁄⁄P < 0.01 compared with the control group. The
KGN cells were infected with Ad-miR-133b or Ad-LacZ at an MOI of 100 for 48 h, and quantitative ChIP was performed with Foxl2 or control antibodies. Co-
immunoprecipitating chromatin fragments were analyzed by real-time PCR using primer sets that spanned 119/+64 bp or 2937/2783 bp in the human StAR promoter
region (C) and 83/+89 bp or 2997/2825 bp in the human CYP19A1 promoter region (D). The results were normalized to total chromatin input. ⁄P < 0.05, ⁄⁄P < 0.01.
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our results from the ChIP assay. Foxl2 is responsible for POF, and
is involved in inﬂammation, apoptosis, reactive oxygen species
metabolism, and granulosa cell tumors [3,5,33]. Here, we deter-
mined that miR-133b downregulated Foxl2 expression in granu-
losa cells, indicating that the miR-133b-mediated inﬂuence on
the ovary is most likely beyond estrogen secretion.
According to the two-cell, two-gonadotropin model describing
ovarian steroid biosynthesis, the common substrate of steroido-
genesis, cholesterol, is transported from the outer to the inner
mitochondrial membrane by StAR [34]. In thecal cells, CYP11A1
catalyzes pregnenolone formation from cholesterol under the
inﬂuence of luteinizing hormone (LH). Pregnenolone is converted
into androgen by CYP17 catalysis. After being metabolized through
a series of substrates, androgens are transported to granulosa cells,
where CYP19 catalyzes the formation of estrogens from androgens
[35]. Therefore, StAR and CYP19A1 are critical molecules in ovarian
estrogen secretion. Based on our results, miR-133b and Foxl2 likely
control estrogen production via StAR and CYP19A1 regulation. As a
vital steroid hormone that is secreted by the ovary, estrogen plays
an essential role in female reproduction. Estrogen is most highly
released by the preovulatory follicles and is closely related to
follicular growth beyond the small antral stage [36]. Estrogen has
local intrafollicular actions, such as increasing follicle number
and size in vivo and in vitro, promoting gonadotropin receptorexpression to facilitate the granulosa cell differentiation, and
stimulating progesterone production to promote corpus luteum
formation and maintenance [37]. As an inhibitor of granulosa cell
apoptosis, estrogen works with many other anti- and pro-apoptotic
factors that are involved in promoting follicle atresia to ensure that
most of the follicles undergo degeneration during growth and
development [38,39]. In addition, estrogen signaling regulates neo-
natal oocyte cyst breakdown and primordial follicle formation [40].
Hence, miR-133b is a potent regulator of various ovarian functions
by enhancing estrogen release from granulosa cells.
Previous studies demonstrated that, in addition to StAR and
CYP19A1, Foxl2 also suppressed CYP11A1 expression at the tran-
scriptional level [25,26,32]. StAR and CYP11A1 are signiﬁcant cat-
alyzing enzymes in progesterone synthesis, which has a key role
in regulating granulosa cell function and follicle rupture during
ovulation [41]. Thus, whether miR-133b and Foxl2 regulate pro-
gesterone levels and affect progesterone-mediated ovarian homeo-
stasis remains unknown.
In summary, miR-133b inhibits Foxl2 expression in human and
mouse granulosa cells by binding to the Foxl2 mRNA seed sequence
in the 30UTR and impairing negative Foxl2-mediated transcriptional
regulation of StAR and CYP19A1, thus stimulating estrogen produc-
tion. The current study provides new insight into miR-133b
function in ovaries. Revealing the crosstalk between miR-133b,
Foxl2, and estrogen synthesis improves our understanding about
2482 A. Dai et al. / FEBS Letters 587 (2013) 2474–2482the signiﬁcant roles played by miRNAs in follicular growth and
ovarian function, and it may provide potential new therapeutic tar-
gets for clinical trials of female infertility disorders, such as POF.
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